Compare FFIN & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FFIN | DFTX |
|---|---|---|
| Founded | 1890 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.9B |
| IPO Year | 1994 | 2020 |
| Metric | FFIN | DFTX |
|---|---|---|
| Price | $32.60 | $38.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $36.50 | ★ $38.50 |
| AVG Volume (30 Days) | 592.3K | ★ 2.2M |
| Earning Date | 04-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 13.46 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $6.61 | N/A |
| P/E Ratio | $33.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.12 | $14.62 |
| 52 Week High | $37.83 | $49.70 |
| Indicator | FFIN | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 37.80 |
| Support Level | $31.35 | $16.37 |
| Resistance Level | $32.98 | $49.13 |
| Average True Range (ATR) | 0.53 | 2.15 |
| MACD | -0.20 | -0.80 |
| Stochastic Oscillator | 0.94 | 6.40 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.